首页> 外文期刊>Diabetes >Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children
【24h】

Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children

机译:二甲双胍对肥胖胰岛素抵抗儿童体重和身体成分的影响

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE-Metformin can decrease adiposity and ameliorate obesity-related comorbid conditions, including abnormalities in glucose homeostasis in adolescents, but there are few data evaluating the efficacy of metformin among younger children. Our objective was to determine whether metformin treatment causes weight loss and improves obesity-related comorbidities in obese children, who are insulin-resistant. RESEARCH DESIGN AND METHODS-This study was a randomized double-blind placebo-controlled trial consisting of 100 severely obese (mean BMI 34.6 ±6.6 kg/m~2) insulin-resistant children aged 6-12 years, randomized to 1,000 mg metformin (n = 53) or placebo (n = 47) twice daily for 6 months, followed by open-label metformin treatment for 6 months. All children and their parents participated in a monthly dietitian-administered weight-reduction program. RESULTS-Eighty-five percent completed the 6-month randomized phase. Children prescribed metformin had significantly greater decreases in BMI (difference -1.09 kg/m~2, CI -1.87 to -0.31, P = 0.006), body weight (difference -3.38 kg, CI -5.2 to -1.57, P < 0.001), BMI Z score (difference between metformin and placebo groups -0.07, CI -0.12 to -0.01, P = 0.02), and fat mass (difference -1.40 kg, CI -2.74 to -0.06, P = 0.04). Fasting plasma glucose (P = 0.007) and homeostasis model assessment (HOMA) insulin resistance index (P = 0.006) also improved more in metformin-treated children than in placebo-treated children. Gastrointestinal symptoms were significantly more prevalent in metformin-treated children, which limited maximal tolerated dosage in 17%. During the 6-month open-label phase, children treated previously with placebo decreased their BMI Z score; those treated continuously with metformin did not significantly change BMI Z score further. CONCLUSIONS-Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program.
机译:目标-二甲双胍可以减少肥胖症并改善肥胖相关的合并症,包括青少年葡萄糖稳态的异常,但很少有数据评估二甲双胍对年幼儿童的疗效。我们的目标是确定二甲双胍治疗是否会导致体重减轻并改善患有胰岛素抵抗的肥胖儿童的肥胖相关合并症。研究设计与方法-这项研究是一项随机双盲安慰剂对照试验,由100名6-12岁的严重肥胖(平均BMI为34.6±6.6 kg / m〜2)胰岛素抵抗儿童组成,随机分配至1,000 mg二甲双胍( n = 53)或安慰剂(n = 47)每天两次,共6个月,然后进行开放标签二甲双胍治疗6个月。所有的孩子及其父母都参加了由营养师管理的每月减重计划。结果85%完成了为期6个月的随机分配阶段。服用二甲双胍的儿童的BMI(差异-1.09 kg / m〜2,CI -1.87至​​-0.31,P = 0.006),体重(差异-3.38 kg,CI -5.2至-1.57,P <0.001)明显更大。 ,BMI Z评分(二甲双胍和安慰剂组之间的差异-0.07,CI -0.12至-0.01,P = 0.02)和脂肪量(差异-1.40 kg,CI -2.74至-0.06,P = 0.04)。空腹血糖(P = 0.007)和体内稳态模型评估(HOMA)胰岛素抵抗指数(P = 0.006)在接受二甲双胍治疗的儿童中也比安慰剂治疗的儿童改善更多。胃肠道症状在接受二甲双胍治疗的儿童中更为普遍,将最大耐受剂量限制在17%。在为期6个月的开放标签阶段,先前接受安慰剂治疗的儿童的BMI Z评分降低;那些用二甲双胍连续治疗的患者并没有进一步显着改变BMI Z评分。结论:二甲双胍对参加低强度减肥计划的肥胖胰岛素抵抗儿童的体重,身体组成和葡萄糖稳态具有适度但有利的作用。

著录项

  • 来源
    《Diabetes》 |2011年第2期|p.477-485|共9页
  • 作者单位

    Unit on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland;

    Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland;

    Department of Nutrition, Hatfleld Clinical Research Center, National Institutes of Health, Bethesda, Maryland;

    Unit on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland;

    Department of Nutrition, Hatfleld Clinical Research Center, National Institutes of Health, Bethesda, Maryland;

    Department of Nutrition, Hatfleld Clinical Research Center, National Institutes of Health, Bethesda, Maryland;

    Department of Diagnostic Radiology and Imaging Sciences, Hatfleld Clinical Research Center, National Institutes of Health, Bethesda, Maryland;

    Unit on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland;

    Unit on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland,Department of Pharmacy,Hatfield Clinical Research Center, National Institutes of Health, Bethesda,Maryland;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:33

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号